PMS2-associated Lynch syndrome: Past, present and future
暂无分享,去创建一个
M. Kloor | K. Kok | R. Sijmons | M. Nielsen | M. Mourits | J. Koornstra | A. Ahadova | M. Suerink | Katarina D. Andini | Noah C. Helderman | Sanne W. Bajwa–ten Broeke | Sanne W Bajwa-Ten Broeke
[1] Hanlee P. Ji,et al. Large Cancer Pedigree Involving Multiple Cancer Genes including Likely Digenic MSH2 and MSH6 Lynch Syndrome (LS) and an Instance of Recombinational Rescue from LS , 2022, Cancers.
[2] M. Kloor,et al. Is HLA type a possible cancer risk modifier in Lynch syndrome? , 2022, International journal of cancer.
[3] Aung Ko Win,et al. Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium , 2022, Hereditary Cancer in Clinical Practice.
[4] K. Wimmer,et al. Teenage-Onset Colorectal Cancers in a Digenic Cancer Predisposition Syndrome Provide Clues for the Interaction between Mismatch Repair and Polymerase δ Proofreading Deficiency in Tumorigenesis , 2022, Biomolecules.
[5] K. Neveling,et al. Non-coding aberrations in mismatch repair genes underlie a substantial part of the missing heritability in Lynch syndrome. , 2022, Gastroenterology.
[6] D. Bishop,et al. Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up , 2022, Cancer prevention research.
[7] P. Skála,et al. Treatment of knee cartilage by cultured stem cells and three dimensional scaffold: a phase I/IIa clinical trial , 2022, International Orthopaedics.
[8] M. Weedon,et al. Influence of family history on penetrance of hereditary cancers in a population setting , 2022, medRxiv.
[9] R. Ward,et al. The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome. , 2022, Genetics in medicine : official journal of the American College of Medical Genetics.
[10] N. Biglia,et al. Gynecological Cancers in Lynch Syndrome: A Comparison of the Histological Features with Sporadic Cases of the General Population , 2022, Journal of clinical medicine.
[11] T. Klein,et al. ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). , 2022, Genetics in medicine : official journal of the American College of Medical Genetics.
[12] A. Italiano,et al. Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Italiano,et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study , 2021, Gynecologic Oncology.
[14] M. Kloor,et al. The coding microsatellite mutation profile of PMS2-deficient colorectal cancer. , 2021, Experimental and molecular pathology.
[15] P. Bork,et al. Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model. , 2021, Gastroenterology.
[16] P. Ascierto,et al. SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study , 2021, Annals of Oncology.
[17] Aung Ko Win,et al. No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study , 2021, Journal of clinical medicine.
[18] Katherine M. Tucker,et al. Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. , 2021, The Lancet. Oncology.
[19] C. V. van Asperen,et al. Universal immunohistochemistry for Lynch Syndrome: a systematic review and meta-analysis of 58,580 colorectal carcinomas. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[20] A. Rustgi,et al. Gene-Specific Variation in Colorectal Cancer Surveillance Strategies for Lynch Syndrome. , 2021, Gastroenterology.
[21] Jose Melendez-Rosado,et al. An Evaluation of the Fecal Microbiome in Lynch Syndrome , 2021, Journal of Gastrointestinal Cancer.
[22] M. Kloor,et al. European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender , 2020, The British journal of surgery.
[23] M. Kloor,et al. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial , 2020, Clinical Cancer Research.
[24] M. Kloor,et al. A Phase I/IIa trial of a frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers. , 2020, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] D. Bishop,et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial , 2020, The Lancet.
[26] E. Savarino,et al. Endoscopic management of gastrointestinal motility disorders – part 2: European Society of Gastrointestinal Endoscopy (ESGE) Guideline , 2020, Endoscopy.
[27] Correction: Cancer risk and survival in path _MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2020, Gut.
[28] David A. Drew,et al. Structure of the Mucosal and Stool Microbiome in Lynch Syndrome. , 2020, Cell host & microbe.
[29] Serena Wong,et al. Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients , 2020, Modern Pathology.
[30] M. Kloor,et al. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. , 2020, Gastroenterology.
[31] J. Cubiella,et al. White-light Endoscopy is Adequate for Lynch Syndrome Surveillance in a Randomized and Non-inferiority Study. , 2020, Gastroenterology.
[32] L. Diaz,et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Zhongliang Deng,et al. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo , 2019, Environmental Health and Preventive Medicine.
[34] I. Tomlinson,et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG) , 2019, Gut.
[35] D. Jäger,et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Kaminski,et al. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline , 2019, Endoscopy.
[37] Aung Ko Win,et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database , 2019, Genetics in Medicine.
[38] Aung Ko Win,et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database , 2019, Genetics in Medicine.
[39] R. Nussbaum,et al. Response to “The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG)” , 2019, Genetics in Medicine.
[40] J. Houwing-Duistermaat,et al. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome , 2019, Genetics in Medicine.
[41] Nobuaki Kono,et al. Nanopore sequencing: Review of potential applications in functional genomics , 2019, Development, growth & differentiation.
[42] P. Møller,et al. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome , 2019, Genetics in Medicine.
[43] K. Stefánsson,et al. Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome , 2019, Journal of Medical Genetics.
[44] Christos Proukakis,et al. Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION , 2019, Molecular genetics & genomic medicine.
[45] Aung Ko Win,et al. Cancer Risks for PMS2-Associated Lynch Syndrome. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] H. Morreau,et al. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2. , 2018, Gastroenterology.
[47] Aung Ko Win,et al. Physical activity and the risk of colorectal cancer in Lynch syndrome , 2018, International journal of cancer.
[48] A. Mattia,et al. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome , 2018, Cancer.
[49] M. Kloor,et al. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome , 2018, International journal of cancer.
[50] G. Chatellier,et al. Impact of an optimized colonoscopic screening program for patients with Lynch syndrome: 6-year results of a specialized French network , 2018, Therapeutic advances in gastroenterology.
[51] C. Deltas. Digenic inheritance and genetic modifiers , 2018, Clinical genetics.
[52] R. Wilcox,et al. Colorectal Carcinomas With Isolated Loss of PMS2 Staining by Immunohistochemistry. , 2018, Archives of pathology & laboratory medicine.
[53] K. Wimmer,et al. Constitutional mismatch repair deficiency in a healthy child: On the spot diagnosis? , 2018, Clinical genetics.
[54] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[55] Brent S. Pedersen,et al. Nanopore sequencing and assembly of a human genome with ultra-long reads , 2017, Nature Biotechnology.
[56] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[57] M. Mcphail,et al. Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis , 2017, Familial Cancer.
[58] J. Kleibeuker,et al. Inflammatory potential of the diet and colorectal tumor risk in persons with Lynch syndrome. , 2017, The American journal of clinical nutrition.
[59] K. Sheahan,et al. The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. , 2017, Critical reviews in oncology/hematology.
[60] P. Møller,et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.
[61] O. Faiz,et al. Risk of metachronous colorectal cancer following colectomy in Lynch syndrome: a systematic review and meta‐analysis , 2017, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[62] A. Sigurdsson,et al. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2 , 2017, Nature Communications.
[63] S. Cascinu,et al. The evolving role of microsatellite instability in colorectal cancer: A review. , 2016, Cancer treatment reviews.
[64] P. Devilee,et al. Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome , 2016, Human mutation.
[65] Aung Ko Win,et al. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[66] M. Kloor,et al. CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome , 2016, Familial Cancer.
[67] M. Kloor,et al. CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome , 2016, Familial Cancer.
[68] James R. Eshleman,et al. Microsatellite Instability as a Biomarker for PD-1 Blockade , 2016, Clinical Cancer Research.
[69] P. Peltomäki. Update on Lynch syndrome genomics , 2016, Familial Cancer.
[70] P. Møller,et al. The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers , 2015, Genetics in Medicine.
[71] P. Møller,et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database , 2015, Gut.
[72] J. Oosterwijk,et al. Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] Aung Ko Win,et al. Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome. , 2015, JAMA.
[74] H. Heneghan,et al. Segmental vs extended colectomy in the management of hereditary nonpolyposis colorectal cancer: a systematic review and meta‐analysis , 2015, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[75] M. Kloor,et al. Mismatch Repair-Deficient Crypt Foci in Lynch Syndrome – Molecular Alterations and Association with Clinical Parameters , 2015, PloS one.
[76] Michael J. McGuffin,et al. A homozygous PMS2 founder mutation with an attenuated constitutional mismatch repair deficiency phenotype , 2015, Journal of Medical Genetics.
[77] P. Møller,et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. , 2015, Journal of Clinical Oncology.
[78] A. Duval,et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘Care for CMMRD’ (C4CMMRD) , 2014, Journal of Medical Genetics.
[79] T. Frebourg,et al. Diversity of the clinical presentation of the MMR gene biallelic mutations , 2014, Familial Cancer.
[80] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[81] F. Nagengast,et al. Do lifestyle factors influence colorectal cancer risk in Lynch syndrome? , 2013, Familial Cancer.
[82] F. Nagengast,et al. Do lifestyle factors influence colorectal cancer risk in Lynch syndrome? , 2013, Familial Cancer.
[83] J. Steiner,et al. Linking Inflammation to Tumorigenesis in a Mouse Model of High‐Fat‐Diet‐Enhanced Colon Cancer , 2013, Cytokine.
[84] J. Kleibeuker,et al. Dietary patterns and colorectal adenomas in Lynch syndrome , 2013, Cancer.
[85] D. Bishop,et al. Edinburgh Research Explorer Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer , 2022 .
[86] J. Mathers,et al. Lynch Syndrome: History, Causes, Diagnosis, Treatment and Prevention (CAPP2 Trial) , 2012, Digestive Diseases.
[87] Axel Benner,et al. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. , 2012, The Lancet. Oncology.
[88] E. Kuipers,et al. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome , 2012, The Journal of pathology.
[89] R. Hofstra,et al. Paediatric intestinal cancer and polyposis due to bi-allelic PMS2 mutations: case series, review and follow-up guidelines. , 2011, European journal of cancer.
[90] S. Lipkin,et al. Mouse models of inherited cancer syndromes. , 2010, Hematology/oncology clinics of North America.
[91] K. Shah. The diagnostic and clinical significance of café-au-lait macules. , 2010, Pediatric clinics of North America.
[92] A. Green,et al. Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of lynch syndrome patients , 2010, Human mutation.
[93] P. Møller,et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe , 2010, Familial Cancer.
[94] Heather Hampel,et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] J. Potter,et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. , 2008, Gastroenterology.
[96] M. Kloor,et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. , 2008, Gastroenterology.
[97] A. de la Chapelle,et al. A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome , 2008, Journal of Medical Genetics.
[98] A. Lindblom,et al. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer , 2006, Familial Cancer.
[99] A. de la Chapelle,et al. Long‐range PCR facilitates the identification of PMS2‐specific mutations , 2006, Human mutation.
[100] J. Jiricny. The multifaceted mismatch-repair system , 2006, Nature Reviews Molecular Cell Biology.
[101] Josef Jiricny,et al. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. , 2005, Gastroenterology.
[102] A. Umar. Lynch Syndrome (HNPCC) and Microsatellite Instability , 2004, Disease markers.
[103] S. Thibodeau,et al. Use of Microsatellite Instability and Immunohistochemistry Testing for the Identification of Individuals at Risk for Lynch Syndrome , 2004, Familial Cancer.
[104] P. Peltomäki. Role of DNA mismatch repair defects in the pathogenesis of human cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] R. Fleischmann,et al. Mutations of two P/WS homologues in hereditary nonpolyposis colon cancer , 1994, Nature.
[106] Robert C. Wolpert,et al. A Review of the , 1985 .
[107] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.